… EGFR mutations. Moving forward, it will be important to include uncommon EGFR mutations
in the first-line molecular analysis of all patients with adenocarcinoma of the lung, as this …

… Several EGFR tyrosine kinase inhibitors (TKIs) are now available for the treatment of EGFR
mutation-positive non-small-cell lung cancer (NSCLC): the first-generation, reversible EGFR …

… to inhibit not only the standard sensitising EGFR mutations occurring in non-small-cell lung
cancer (NSCLC), but also T790M, an exon 20 point mutation, which commonly emerges as a …

… with cancer treatment 15 . Several clinical trials have been performed to evaluate the
efficacy and safety of treatments for lung cancer patients with EGFR mutations 16 . EGFR is a …

… had generally a better impact on features for EGFR compared to KRAS status prediction, its
… successful prediction of EGFR and KRAS mutation statuses in lung cancer patients. Thus, by …

… Therefore, for patients with EGFR mutation positivity in advanced lung cancer, osimertinib
has established its unshakable position in the targeted treatment of NSCLC due to its …

… The most common type of activating EGFR mutation is the in-frame deletion of … lung cancer
in patients with EGFR or ALK-wildtype NSCLC. Clinical trials evidence suggests that EGFR- …

… to EGFR mutations conducted before EGFR mutations were … subset of patients with EGFR
mutation treated with erlotinib. … with lung cancer selected with respect to EGFR mutation …

… non–small cell lung cancer (NSCLC) with confirmed EGFR mutations who received
osimertinib monotherapy from 2014 to 2019 at the Osaka International Cancer Institute (Osaka, …

… (EGFR)-mutated non-small cell lung cancer (NSCLC) patients and T790M-mediated resistance.
We investigated the clinical utility of EGFR mutation … in metastatic, EGFR-mutant NSCLC …